-

Gene Therapies, Cell Therapies, and COVID-19 Vaccines Viral Vector Contract Manufacturing Outlook Report 2021: Spotlight on AstraZeneca's COVID-19 Vaccine, Luxturna, Zolgensma, Emergent, Catalent - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Outlook for Viral Vector Contract Manufacturing - Gene Therapies, Cell Therapies, and COVID-19 Vaccines" report has been added to ResearchAndMarkets.com's offering.

This report examines the approvals and manufacturing outlook for three drug molecule types that all require viral vectors in their production: gene therapies, gene-modified cell therapies, and recombinant vector vaccines.

The report is critical for benchmarking the CMO industry's capacity to manufacture these vital vaccines and drugs and forecasting future approvals.

Reasons to Buy

  • Detailed view of the geographic distribution of viral vector contract manufacturing facilities worldwide and the proportion belonging to dedicated CMOs and excess capacity manufacturers
  • Leader and disruptor companies in the viral vector space
  • Analysis of pipeline and marketed gene therapies, cell therapies, and recombinant vector vaccines, by geography, development stage, and clinical trials
  • A detailed model forecasting future gene therapy, cell therapy, and recombinant vector vaccine approvals, and associated manufacturing volumes
  • Contract manufacturing agreements for the active pharmaceutical ingredient (API) component of these vaccines and therapies

Key Topics Covered:

1 Executive Summary

2 Players

3 Technology Briefing

3.1 Gene Therapies

3.2 Gene-Modified Cell Therapies

3.3 Recombinant Vector Vaccines

3.4 What Are Viral Vectors?

4 Trends

5 Industry Analysis

5.1 Pipeline Therapies and Vaccines

5.2 Marketed Therapies and Vaccines

5.3 Clinical Trials

5.3.1 Gene Therapies and Gene-Modified Cell Therapies

5.3.2 Recombinant Vector Vaccines

5.4 Top Therapy Areas and Indications

5.4.1 Gene Therapies and Gene-Modified Cell Therapies

5.4.2 Recombinant Vector Vaccines

6 Approvals and Volume Model

6.1 Projected Sales

6.1.1 Spotlight on Luxturna

6.1.2 Spotlight on Zolgensma

6.1.3 Spotlight on AstraZeneca's COVID-19 Vaccine

6.1.4 Combined Recombinant Vector Vaccines

6.2 Gene Therapy and Gene-Modified Cell Therapy Volume Model

6.2.1 Product Approval

6.2.2 Benchmark Therapies

6.2.3 Commercial Demand

6.2.4 Clinical Demand

6.3 Recombinant Vector Vaccine Volume Model

6.4 Bioreactor Capacity

7 Value Chain - Contract Manufacturing Capabilities

7.1 Viral Vector Manufacturing Sites

7.2 Company Investments in Viral Vector Manufacturing

7.3 Spotlight on Emergent

7.4 Spotlight on Catalent

7.5 Spotlight on Thermo Fisher Scientific/Patheon

7.6 Other Company Investments

7.7 Contract Manufacturing Agreements

7.8 What It Means

7.8.1 The Future of Manufacturing

7.8.2 Cell Lines and Automation

8 Companies

9 Appendix

Companies Mentioned

  • 4D Molecular Therapeutics Inc
  • Abeona Therapeutics Inc
  • ActogeniX NV
  • Adaptimmune Ltd
  • Adrenas Therapeutics Inc Aspa Therapeutics Inc BridgeBio Pharma Inc
  • Advanced BioScience Laboratories Inc
  • Advantagene Inc
  • Advaxis Inc
  • Advent Srl
  • AGC Biologics SpA
  • Ajinomoto Bio-Pharma Services
  • Albany Molecular Research Inc
  • Albert B. Sabin Vaccine Institute Inc
  • Aldevron LLC
  • Almac Group Ltd
  • Altimmune Inc
  • Amicus Therapeutics Inc
  • Anchiano Therapeutics Ltd
  • Aruvant Sciences Inc
  • ASC Therapeutics Inc
  • Aslan Pharmaceuticals Ltd
  • Aspen Pharmacare Holdings Ltd
  • AstraZeneca
  • University of Oxford
  • Attwill Medical Solutions
  • Batavia Biosciences BV
  • Baxter Biopharma Solutions
  • Benitec Biopharma Inc
  • BioCell Corp Ltd
  • Biological E Ltd
  • BioReliance Corp
  • bluebird bio Inc
  • Boehringer Ingelheim Biopharmaceuticals GmbH Boehringer Ingelheim RCV GmbH & Co KG
  • BriaCell Therapeutics Corp
  • Caladrius Biosciences Inc
  • Candel Therapeutics
  • Catalent Inc
  • Cell and Gene Therapy Catapult
  • Cell Therapies Pty Ltd
  • Cellectis SA
  • CELLforCURE
  • Celsion Corp
  • Centaur Biopharmaceutical Services Inc
  • Centre C3i
  • Chinook Therapeutics Inc
  • City of Hope
  • Coalition for Epidemic Preparedness Innovations Public Health Vaccines LLC
  • Cobra Biologics Ltd
  • CombiGene AB
  • Corautus Genetics Inc. (Inactive)
  • CRISPR Therapeutics AG
  • Daiichi Sankyo Biotech Co Ltd
  • Decibel Therapeutics Inc
  • DiNAQOR AG
  • Dompe Farmaceutici SpA
  • Editas Medicine Inc
  • Eiger BioPharmaceuticals Inc
  • ElevateBio LLC
  • Emergent BioSolutions Inc
  • enGene Inc
  • Flexion Therapeutics Inc
  • Forte Biosciences Inc
  • Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung eV
  • Freeline Therapeutics Holdings Plc
  • Fujifilm Diosynth Biotechnologies USA Inc
  • Gamaleya Federal Research Center of Epidemiology and Microbiology
  • Genethon SA Sarepta Therapeutics Inc
  • Genprex Inc
  • Genscript Biotech Corp
  • GenVec LLC
  • GeoVax Labs Inc
  • German Center for Infection Research
  • GlaxoSmithKline Plc
  • Grand River Aseptic Manufacturing Inc
  • Halix BV
  • Handl Therapeutics BV
  • Helocyte Biosciences Inc
  • Helocyte, Inc.
  • Hookipa Pharma Inc
  • IDT Biologika GmbH
  • IN8bio Inc
  • Indapta Therapeutics Inc
  • Innobation Co Ltd
  • Insud Pharma
  • International AIDS Vaccine Initiative
  • Ion Channel Innovations LLC
  • iosBio Pharma Ltd
  • Iovance Biotherapeutics Inc
  • IVERIC bio Inc
  • Janssen Pharmaceutica
  • JCR Pharmaceuticals Co Ltd
  • Jenner Institute
  • Johnson & Johnson
  • Juventas Therapeutics Inc
  • KBI Biopharma Inc
  • Kite Pharma Inc
  • Laboratorio Reig Jofre SA
  • Lentigen Technology Inc
  • Les Laboratoires Servier SAS
  • Lonza Group Ltd
  • Lysogene SAS
  • Massachusetts General Hospital
  • MaSTherCell SA
  • MaxCyte Inc
  • Merck KGaA
  • MilliporeSigma
  • Minaris Regenerative Medicine GmbH
  • Minaris Regenerative Medicine LLC
  • Minaris Regenerative Medicine LLC Showa Denko Materials Co Ltd
  • MTG Biotherapeutics Inc
  • Mustang Bio Inc
  • Noga Therapeutics Ltd
  • Novartis
  • Novasep Holding SAS
  • Novavax Inc
  • Ology Bioservices Inc
  • OncoSec Medical Inc
  • Oncternal Therapeutics
  • Orchard Therapeutics Plc
  • Otsuka Holdings Co Ltd
  • Oxford BioMedica Plc
  • Oxford-Emergent Tuberculosis Consortium Limited (Inactive)
  • Passage Bio Inc
  • Patheon
  • Pfizer Inc
  • Pharmasyntez
  • Poseida Therapeutics Inc
  • Prevail Therapeutics Inc
  • ProBioGen AG
  • Profectus BioSciences Inc
  • Provecs Medical GmbH
  • PTC Therapeutics Inc
  • Rega Institute for Medical Research
  • RegenxBio Inc
  • ReiThera Srl
  • Renova Therapeutics Inc
  • Richter-Helm BioLogics GmbH & Co KG
  • Rocket Pharmaceuticals Inc
  • SanBio Company Limited
  • Sangamo Therapeutics France SAS
  • Sanofi
  • Sarepta Therapeutics Inc
  • Scenic Biotech BV
  • Selecta Biosciences Inc
  • Selexis SA
  • Sensorion SA
  • SGS Life Science Services
  • Sio Gene Therapies Inc
  • SK Bioscience
  • Spark Therapeutics Inc
  • Symbiosis Pharmaceutical Services Ltd
  • Synlogic Inc
  • Takara Bio Inc
  • Taysha Gene Therapies
  • TCR2 Therapeutics Inc
  • Themis Bioscience GmbH
  • T-Knife GmbH
  • Tonix Pharmaceuticals Holding Corp
  • Triumvira Immunologics Inc
  • TTY Biopharm Co Ltd
  • Ultragenyx Pharmaceutical Inc
  • UniQure NV
  • University of Oxford
  • Valneva SE
  • Vaxart Inc
  • VGXI Inc
  • Vibalogics GmbH
  • Vigene Biosciences Inc
  • ViGeneron GmbH
  • Vir Biotechnology Inc
  • Viralgen
  • Vivebiotech SL
  • Vivet Therapeutics SAS
  • Wacker Chemie AG
  • Waisman Biomanufacturing
  • WuXi AppTec
  • Xyphos Biosciences Inc
  • Yposkesi SAS
  • Zhejiang Hisun Pharmaceutical Co Ltd
  • ZIOPHARM Oncology Inc

For more information about this report visit https://www.researchandmarkets.com/r/vamfb1

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Poland Investment Funds and Asset Management Market Report 2026, Profiles of TFI, Pekao, Santander, PKO, Allianz, Goldman Sachs - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Investment Funds and Asset Management Market in Poland, 2024-2026" report has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive overview of the investment funds and asset management sector in Poland. Analysis covers the main pillars of the market, including: mutual funds, insurance, and pension assets. The report also mid-term forecast of key volumes for the period 2025-2027. The data has been presented in a form of horizontal pr...

Europe Data Center Colocation Market Outlook & Forecast Report 2025-2030 Featuring Major Players - Digital Realty, Equinix, NTT DATA, Global Switch, CyrusOne, Ark Data Centres - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Europe Data Center Colocation Market - Industry Outlook & Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering. The Europe Data Center Colocation Market was valued at USD 9.45 Billion in 2024, and is projected to reach USD 35.73 Billion by 2030, rising at a CAGR of 24.82%. The Europe data center colocation market is expected to witness cumulative investments of approximately $144.03 billion, of which, the Western Europe is slated to ac...

GCC Construction Equipment Market Research Report 2025-2030 Featuring Key Vendors - Caterpillar, Komatsu, Volvo, Hitachi, SANY, XCMG, JCB, Liebherr, Kobelco, and Zoomlion - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "GCC Construction Equipment Market Research Report 2025-2030" report has been added to ResearchAndMarkets.com's offering. The GCC Construction Equipment Market was sized at 68,499 Units in 2024, and is projected to reach 94,499 Units by 2030, rising at a CAGR of 5.51%. Governments in the UAE and Saudi Arabia continue to prioritize urban growth and diversification, with Dubai's long-term 2040 Urban Master Plan and the Saudi Vision 2030-linked mega-projects fuelling o...
Back to Newsroom